



**Merck & Co., Inc.
Financial Highlights Package
Second Quarter 2014
Table of Contents**

Table 1: GAAP P&L.....	1
Table 1a: GAAP P&L – Current Year and Prior Year by Quarter.....	2
Table 2a: GAAP to Non-GAAP P&L Reconciliation 2Q14	3
Table 2b: GAAP to Non-GAAP P&L Reconciliation June YTD 14	4
Table 2c: GAAP to Non-GAAP P&L Reconciliation 2Q13.....	5
Table 2d: GAAP to Non-GAAP P&L Reconciliation June YTD 13	6
Table 3: Sales – Current Year and Prior Year by Quarter	7
Table 3a: Sales – U.S. / Ex- U.S. 2Q14	8
Table 3b: Sales – U.S. / Ex- U.S. June YTD 14.....	9
Table 3c: Sales – Pharmaceutical Geographic Split	10
Table 4: Equity Income / JV Sales / Other (Income) Expense	11

MERCK & CO., INC.
CONSOLIDATED STATEMENT OF INCOME - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)

Table 1

	GAAP		% Change	GAAP		% Change
	2Q14	2Q13		June YTD 2014	June YTD 2013	
Sales	\$ 10,934	\$ 11,010	-1%	\$ 21,198	\$ 21,681	-2%
Costs, Expenses and Other						
Materials and production ⁽¹⁾	4,893	4,284	14%	8,796	8,243	7%
Marketing and administrative ⁽¹⁾	2,973	3,140	-5%	5,707	6,126	-7%
Research and development ⁽¹⁾	1,664	2,101	-21%	3,238	4,008	-19%
Restructuring costs ⁽²⁾	163	155	5%	288	274	5%
Equity income from affiliates ⁽³⁾	(92)	(116)	-21%	(217)	(249)	-13%
Other (income) expense, net ⁽¹⁾⁽⁴⁾	(558)	201	*	(596)	484	*
Income Before Taxes	1,891	1,245	52%	3,982	2,795	42%
Income Tax (Benefit) Provision	(142)	310		218	244	
Net Income	2,033	935	*	3,764	2,551	48%
Less: Net Income Attributable to Noncontrolling Interests	29	29		55	52	
Net Income Attributable to Merck & Co., Inc.	\$ 2,004	\$ 906	*	\$ 3,709	\$ 2,499	48%
Earnings per Common Share Assuming Dilution	\$ 0.68	\$ 0.30	*	\$ 1.25	\$ 0.82	52%
Average Shares Outstanding Assuming Dilution	2,949	3,010		2,957	3,030	
Tax Rate ⁽⁵⁾	-7.5%	24.9%		5.5%	8.7%	

* 100% or greater

(1) Amounts include the impact of acquisition and divestiture-related costs, restructuring costs and certain other items. See accompanying tables for details.

(2) Represents separation and other related costs associated with restructuring activities under the company's formal restructuring programs.

(3) Primarily reflects equity income from the AstraZeneca LP and Sanofi Pasteur MSD partnerships.

(4) Other (income) expense, net in the second quarter and first six months of 2014 includes a gain of \$741 million related to AstraZeneca's option exercise. In addition, other (income) expense, net in the first six months of 2014 includes net gains of \$168 million related to the divestiture of the company's Sirna Therapeutics, Inc. subsidiary. Other (income) expense, net in the first six months of 2013 reflects approximately \$140 million of exchange losses as a result of a Venezuelan currency devaluation.

(5) The effective income tax rates for the second quarter and first six months of 2014 reflect a net benefit of \$517 million recorded in connection with AstraZeneca's option exercise. In addition, the effective income tax rate for the first six months of 2014 reflects a benefit of approximately \$300 million associated with a capital loss generated in the first quarter of 2014.

The effective income tax rates for the second quarter and first six months of 2013 reflect benefits from reductions in tax reserves upon expiration of applicable statute of limitations. In addition, the effective tax rate for the first six months of 2013 reflects the favorable impact of tax legislation enacted in the first quarter of 2013, as well as a benefit of approximately \$160 million associated with the resolution of a previously disclosed federal income tax issue.

MERCK & CO., INC.
CONSOLIDATED STATEMENT OF INCOME - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)

Table 1a

	2014			2013						% Change	
	1Q	2Q	June YTD	1Q	2Q	June YTD	3Q	4Q	Full Year	2Q	June YTD
Sales	\$ 10,264	\$ 10,934	\$ 21,198	\$ 10,671	\$ 11,010	\$ 21,681	\$ 11,032	\$ 11,319	\$ 44,033	-1%	-2%
Costs, Expenses and Other											
Materials and production	3,903	4,893	8,796	3,959	4,284	8,243	4,104	4,607	16,954	14%	7%
Marketing and administrative	2,734	2,973	5,707	2,987	3,140	6,126	2,803	2,982	11,911	-5%	-7%
Research and development	1,574	1,664	3,238	1,907	2,101	4,008	1,660	1,836	7,503	-21%	-19%
Restructuring costs	125	163	288	119	155	274	870	565	1,709	5%	5%
Equity income from affiliates	(124)	(92)	(217)	(133)	(116)	(249)	(102)	(53)	(404)	-21%	-13%
Other (income) expense, net	(39)	(558)	(596)	282	201	484	172	157	815	*	*
Income Before Taxes	2,091	1,891	3,982	1,550	1,245	2,795	1,525	1,225	5,545	52%	42%
Income Tax Provision (Benefit)	360	(142)	218	(66)	310	244	375	410	1,028		
Net Income	1,731	2,033	3,764	1,616	935	2,551	1,150	815	4,517	*	48%
Less: Net Income Attributable to Noncontrolling Interests	26	29	55	23	29	52	26	34	113		
Net Income Attributable to Merck & Co., Inc.	\$ 1,705	\$ 2,004	\$ 3,709	\$ 1,593	\$ 906	\$ 2,499	\$ 1,124	\$ 781	\$ 4,404	*	48%
Earnings per Common Share Assuming Dilution	\$ 0.57	\$ 0.68	\$ 1.25	\$ 0.52	\$ 0.30	\$ 0.82	\$ 0.38	\$ 0.26	\$ 1.47	*	52%
Average Shares Outstanding Assuming Dilution	2,971	2,949	2,957	3,053	3,010	3,030	2,960	2,959	2,996		
Tax Rate	17.2%	-7.5%	5.5%	-4.3%	24.9%	8.7%	24.6%	33.5%	18.5%		

* 100% or greater

Sum of quarterly amounts may not equal year-to-date amounts due to rounding.

MERCK & CO., INC.
CONSOLIDATED STATEMENT OF INCOME
GAAP TO NON-GAAP RECONCILIATION
SECOND QUARTER 2014
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)

Table 2a

	GAAP	Acquisition and Divestiture- Related Costs ⁽¹⁾	Restructuring Costs ⁽²⁾	Certain Other Items ⁽³⁾	Adjustment Subtotal	Non-GAAP
Sales	\$ 10,934					\$ 10,934
Costs, Expenses and Other						
Materials and production	4,893	1,724	171		1,895	2,998
Marketing and administrative	2,973	32	44		76	2,897
Research and development	1,664		43		43	1,621
Restructuring costs	163		163		163	-
Equity income from affiliates	(92)					(92)
Other (income) expense, net	(558)			(741)	(741)	183
Income Before Taxes	1,891	(1,756)	(421)	741	(1,436)	3,327
Taxes on Income	(142)				(947) ⁽⁴⁾	805
Net Income	2,033				(489)	2,522
Less: Net Income Attributable to Noncontrolling Interests	29					29
Net Income Attributable to Merck & Co., Inc.	\$ 2,004				\$ (489)	\$ 2,493
Earnings per Common Share Assuming Dilution	\$ 0.68					\$ 0.85
Average Shares Outstanding Assuming Dilution	2,949					2,949
Tax Rate	-7.5%					24.2%

Merck is providing non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors' understanding of the company's performance. This information should be considered in addition to, but not in lieu of, information prepared in accordance with GAAP.

(1) Amounts included in materials and production costs reflect expenses of \$1.1 billion for the amortization of intangible assets recognized as a result of mergers and acquisitions, as well as \$660 million of impairment charges on product intangibles. Amounts included in marketing and administrative expenses reflect merger integration costs, as well as transaction and certain other costs related to business acquisitions and divestitures.

(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to actions under the company's formal restructuring programs.

(3) Represents the gain related to AstraZeneca's option exercise.

(4) Represents the estimated tax impact on the reconciling items, including a net benefit of \$517 million recorded in connection with AstraZeneca's option exercise.

MERCK & CO., INC.
CONSOLIDATED STATEMENT OF INCOME
GAAP TO NON-GAAP RECONCILIATION
SIX MONTHS ENDED JUNE 30, 2014
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)

Table 2b

	GAAP	Acquisition and Divestiture- Related Costs ⁽¹⁾	Restructuring Costs ⁽²⁾	Certain Other Items ⁽³⁾	Adjustment Subtotal	Non-GAAP
Sales	\$ 21,198					\$ 21,198
Costs, Expenses and Other						
Materials and production	8,796	2,850	290		3,140	5,656
Marketing and administrative	5,707	43	75		118	5,589
Research and development	3,238		94		94	3,144
Restructuring costs	288		288		288	-
Equity income from affiliates	(217)					(217)
Other (income) expense, net	(596)			(741)	(741)	145
Income Before Taxes	3,982	(2,893)	(747)	741	(2,899)	6,881
Taxes on Income	218				(1,514) ⁽⁴⁾	1,732
Net Income	3,764				(1,385)	5,149
Less: Net Income Attributable to Noncontrolling Interests	55					55
Net Income Attributable to Merck & Co., Inc.	\$ 3,709				\$ (1,385)	\$ 5,094
Earnings per Common Share Assuming Dilution	\$ 1.25					\$ 1.72
Average Shares Outstanding Assuming Dilution	2,957					2,957
Tax Rate	5.5%					25.2%

Merck is providing non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors' understanding of the company's performance. This information should be considered in addition to, but not in lieu of, information prepared in accordance with GAAP.

(1) Amounts included in materials and production costs reflect expenses of \$2.2 billion for the amortization of intangible assets recognized as a result of mergers and acquisitions, as well as \$660 million of impairment charges on product intangibles. Amounts included in marketing and administrative expenses reflect merger integration costs, as well as transaction and certain other costs related to business acquisitions and divestitures.

(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to actions under the company's formal restructuring programs.

(3) Represents the gain related to AstraZeneca's option exercise.

(4) Represents the estimated tax impact on the reconciling items, including a net benefit of approximately \$517 million recorded in connection with AstraZeneca's option exercise, as well as a benefit of approximately \$300 million associated with a capital loss generated in the first quarter.

MERCK & CO., INC.
CONSOLIDATED STATEMENT OF INCOME
GAAP TO NON-GAAP RECONCILIATION
SECOND QUARTER 2013
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)

Table 2c

	GAAP	Acquisition and Divestiture- Related Costs ⁽¹⁾	Restructuring Costs ⁽²⁾	Certain Other Items	Adjustment Subtotal	Non-GAAP
Sales	\$ 11,010					\$ 11,010
Costs, Expenses and Other						
Materials and production	4,284	1,515	93		1,608	2,676
Marketing and administrative	3,140	19	16		35	3,105
Research and development	2,101	234	14		248	1,853
Restructuring costs	155		155		155	-
Equity income from affiliates	(116)					(116)
Other (income) expense, net	201			(13)	(13)	214
Income Before Taxes	1,245	(1,768)	(278)	13	(2,033)	3,278
Taxes on Income	310				(409) ⁽³⁾	719
Net Income	935				(1,624)	2,559
Less: Net Income Attributable to Noncontrolling Interests	29					29
Net Income Attributable to Merck & Co., Inc.	\$ 906				\$ (1,624)	\$ 2,530
Earnings per Common Share Assuming Dilution	\$ 0.30					\$ 0.84
Average Shares Outstanding Assuming Dilution	3,010					3,010
Tax Rate	24.9%					21.9%

Merck is providing non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors' understanding of the company's performance. This information should be considered in addition to, but not in lieu of, information prepared in accordance with GAAP.

(1) Amounts included in materials and production costs reflect expenses of \$1.2 billion for the amortization of intangible assets recognized as a result of mergers and acquisitions, as well as \$330 million of impairment charges on product intangibles. Amounts included in marketing and administrative expenses reflect merger integration costs. Amounts included in research and development expenses represent in-process research and development ("IPR&D") impairment charges.

(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to actions under the company's formal restructuring programs.

(3) Represents the estimated tax impact on the reconciling items.

MERCK & CO., INC.
CONSOLIDATED STATEMENT OF INCOME
GAAP TO NON-GAAP RECONCILIATION
SIX MONTHS ENDED JUNE 30, 2013
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)

Table 2d

	GAAP	Acquisition and Divestiture- Related Costs ⁽¹⁾	Restructuring Costs ⁽²⁾	Certain Other Items	Adjustment Subtotal	Non-GAAP
Sales	\$ 21,681					\$ 21,681
Costs, Expenses and Other						
Materials and production	8,243	2,699	136		2,835	5,408
Marketing and administrative	6,126	42	33		75	6,051
Research and development	4,008	264	29		293	3,715
Restructuring costs	274		274		274	-
Equity income from affiliates	(249)					(249)
Other (income) expense, net	484			(13)	(13)	497
Income Before Taxes	2,795	(3,005)	(472)	13	(3,464)	6,259
Taxes on Income	244				(848) ⁽³⁾	1,092
Net Income	2,551				(2,616)	5,167
Less: Net Income Attributable to Noncontrolling Interests	52					52
Net Income Attributable to Merck & Co., Inc.	\$ 2,499				\$ (2,616)	\$ 5,115
Earnings per Common Share Assuming Dilution	\$ 0.82					\$ 1.69
Average Shares Outstanding Assuming Dilution	3,030					3,030
Tax Rate	8.7%					17.4%

Merck is providing non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors' understanding of the company's performance. This information should be considered in addition to, but not in lieu of, information prepared in accordance with GAAP.

(1) Amounts included in materials and production costs reflect expenses of \$2.4 billion for the amortization of intangible assets recognized as a result of mergers and acquisitions, as well as \$330 million of impairment charges on product intangibles. Amounts included in marketing and administrative expenses reflect merger integration costs. Amounts included in research and development expenses represent in-process research and development ("IPR&D") impairment charges.

(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to actions under the company's formal restructuring programs.

(3) Represents the estimated tax impact on the reconciling items, as well as a benefit of approximately \$160 million associated with the resolution of a previously disclosed federal income tax issue.

MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
(AMOUNTS IN MILLIONS)

Table 3

	2014			2013						% Change	
	1Q	2Q	June YTD	1Q	2Q	June YTD	3Q	4Q	Full Year	2Q	June YTD
TOTAL SALES ⁽¹⁾	\$10,264	\$10,934	\$21,198	\$10,671	\$11,010	\$21,681	\$11,032	\$11,319	\$44,033	-1	-2
PHARMACEUTICAL	8,451	9,087	17,538	8,891	9,310	18,201	9,475	9,760	37,437	-2	-4
Primary Care and Women's Health											
Cardiovascular											
Zetia	611	717	1,328	629	650	1,279	662	716	2,658	10	4
Vytorin	361	417	777	394	417	810	396	436	1,643		-4
Diabetes											
Januvia	858	1,058	1,916	884	1,072	1,956	927	1,121	4,004	-1	-2
Janumet	476	519	995	409	474	883	442	503	1,829	9	13
General Medicine & Women's Health											
NuvaRing	168	178	346	151	171	322	170	193	686	4	7
Implanon	102	119	221	84	102	187	96	120	403	16	18
Follistim AQ	110	102	213	122	134	257	124	101	481	-24	-17
Dulera	102	103	205	68	79	147	82	95	324	30	39
Hospital and Specialty											
Hepatitis											
PegIntron	112	103	216	126	142	268	104	124	496	-27	-19
Victrelis	59	46	105	110	116	226	121	81	428	-60	-53
HIV											
Isentress	390	453	843	362	412	775	427	442	1,643	10	9
Hospital											
Cancidas	166	156	322	162	163	326	151	183	660	-5	-1
Invanz	114	134	249	110	120	230	130	128	488	12	8
Noxafil	74	98	172	65	71	136	75	98	309	38	26
Bridion	73	82	155	63	69	131	75	82	288	20	18
Primaxin	71	81	151	84	85	168	88	79	335	-5	-10
Immunology											
Remicade	604	607	1,211	549	527	1,076	574	620	2,271	15	13
Simponi	157	174	330	108	120	228	126	146	500	44	45
Other											
Cosopt / Trusopt	99	100	198	105	103	209	104	103	416	-3	-5
Oncology											
Emend	122	144	266	116	135	250	123	134	507	7	6
Temodar	83	93	176	216	219	434	162	111	708	-57	-59
Diversified Brands											
Respiratory											
Nasonex	312	258	570	385	325	711	297	327	1,335	-21	-20
Singulair	271	284	554	337	281	618	280	298	1,196	1	-10
Clarinet	62	69	131	61	64	125	54	55	235	7	5
Other											
Cozaar / Hyzaar	205	214	419	267	255	522	238	246	1,006	-16	-20
Arcoxia	128	141	268	121	121	242	112	131	484	16	11
Fosamax	123	121	245	137	144	281	140	139	560	-16	-13
Zocor	64	69	133	82	74	156	65	79	301	-8	-15
Propecia	74	58	131	68	67	135	71	77	283	-14	-3
Remeron	50	40	90	52	53	106	44	56	206	-26	-15
Vaccines											
Gardasil	383	409	792	390	383	773	665	394	1,831	7	3
ProQuad, M-M-R II and Varivax	280	326	606	272	339	611	421	273	1,306	-4	-1
RotaTeq	169	147	316	162	144	306	201	129	636	3	3
Zostavax	142	156	298	168	141	309	185	264	758	11	-3
Pneumovax 23	101	102	203	111	108	219	193	241	653	-6	-7
Other Pharmaceutical ⁽²⁾	1,175	1,209	2,387	1,361	1,430	2,789	1,350	1,435	5,570	-15	-14
ANIMAL HEALTH	813	872	1,685	840	851	1,691	800	871	3,362	2	
CONSUMER CARE ⁽³⁾	546	583	1,130	571	490	1,061	443	390	1,894	19	6
Claritin OTC	170	153	323	177	78	256	123	92	471	95	26
Other Revenues ⁽⁴⁾	454	392	845	369	359	727	314	298	1,340	9	16
Astra	147	316	463	262	245	507	220	193	920	29	-9

Sum of quarterly amounts may not equal year-to-date amounts due to rounding.

⁽¹⁾ Only select products are shown.

⁽²⁾ Includes Pharmaceutical products not individually shown above. Other Vaccines sales included in Other Pharmaceutical were \$98 million and \$76 million for the first and second quarters of 2014. Other Vaccines sales included in Other Pharmaceutical were \$53 million, \$86 million, \$127 million, and \$101 million for the first, second, third, and fourth quarters of 2013, respectively.

⁽³⁾ The decrease in Consumer Care sales in the second quarter and full year of 2013 resulted from the termination in China of distribution arrangements and a reversal of sales previously made to those distributors, together with associated termination costs.

⁽⁴⁾ Other revenues are comprised primarily of alliance revenue, third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities. On October 1, 2013, the Company divested a substantial portion of its third-party manufacturing sales. In addition, Other revenues in the fourth quarter and full year of 2013 reflect \$50 million of revenue for the out-license of a pipeline compound.

MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
SECOND QUARTER 2014
(AMOUNTS IN MILLIONS)

Table 3a

	Global			U.S.			International		
	2Q 2014	2Q 2013	% Change	2Q 2014	2Q 2013	% Change	2Q 2014	2Q 2013	% Change
TOTAL SALES ⁽¹⁾	\$10,934	\$11,010	-1	\$4,429	\$4,608	-4	\$6,505	\$6,402	2
PHARMACEUTICAL	9,087	9,310	-2	3,462	3,689	-6	5,625	5,622	
Primary Care and Women's Health									
Cardiovascular									
Zetia	717	650	10	408	351	16	309	299	3
Vytorin	417	417		158	170	-7	259	247	5
Diabetes & Obesity									
Januvia	1,058	1,072	-1	566	571	-1	492	501	-2
Janumet	519	474	9	235	235		284	239	19
General Medicine & Women's Health									
NuvaRing	178	171	4	112	107	4	66	64	4
Implanon	119	102	16	67	51	31	52	51	2
Follistim AQ	102	134	-24	30	62	-51	72	73	-1
Dulera	103	79	30	98	75	31	5	4	21
Hospital and Specialty									
Hepatitis									
PegIntron	103	142	-27	8	13	-40	95	129	-26
Victrelis	46	116	-60	1	52	-99	46	64	-29
HIV									
Isentress	453	412	10	228	218	5	225	195	16
Hospital									
Candidas	156	163	-5	4	8	-49	152	155	-2
Invanz	134	120	12	64	61	4	71	59	20
Noxafil	98	71	38	35	22	62	63	49	28
Bridion	82	69	20				82	69	20
Primaxin	81	85	-5		4	*	81	81	
Immunology									
Remicade	607	527	15				607	527	15
Simponi	174	120	44				174	120	44
Other									
Cosopt / Trusopt	100	103	-3		5	-97	99	98	1
Oncology									
Emend	144	135	7	78	74	5	66	61	9
Temodar	93	219	-57	5	108	-95	88	111	-21
Diversified Brands									
Respiratory									
Nasonex	258	325	-21	141	177	-20	117	148	-21
Singular	284	281	1	8	15	-43	275	266	4
Clarinet	69	64	7	5	2	*	64	63	2
Other									
Cozaar / Hyzaar	214	255	-16	8	5	79	206	250	-18
Arcoxia	141	121	16				141	121	16
Fosamax	121	144	-16	6	4	27	116	140	-17
Zocor	69	74	-8	5	6	-11	63	68	-7
Propecia	58	67	-14	5	5	-5	53	62	-15
Remeron	40	53	-26	1	1	-15	39	52	-26
Vaccines									
Gardasil	409	383	7	294	252	16	115	131	-12
ProQuad, M-M-R II and Varivax	326	339	-4	276	301	-8	50	38	31
RotaTeq	147	144	3	101	98	4	46	46	1
Zostavax	156	141	11	116	122	-5	40	19	*
Pneumovax 23	102	108	-6	85	80	6	17	28	-38
Other Pharmaceutical ⁽²⁾	1,209	1,430	-15	314	434	-28	895	994	-10
ANIMAL HEALTH	872	851	2	185	219	-16	687	632	9
CONSUMER CARE ⁽³⁾	583	490	19	406	390	4	177	99	78
Claritin OTC	153	78	95	110	108	2	44	(29)	*
Other Revenues ⁽⁴⁾	392	359	9	376	310	21	16	48	-66
Astra	316	245	29	316	245	29			

* 100% or greater

⁽¹⁾ Only select products are shown.

⁽²⁾ Includes Pharmaceutical products not individually shown above. Other Vaccines sales included in Other Pharmaceutical were \$76 million and \$86 million on a global basis for second quarter 2014 and 2013, respectively.

⁽³⁾ Second quarter 2013 includes a reduction to Consumer Care sales that reflects the termination in China of distribution arrangements and a reversal of sales previously made to those distributors, together with associated termination costs.

⁽⁴⁾ Other revenues are comprised primarily of alliance revenue, third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities. On October 1, 2013, the Company divested a substantial portion of its third-party manufacturing sales.

MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
JUNE YEAR-TO-DATE 2014
(AMOUNTS IN MILLIONS)

Table 3b

	Global			U.S.			International		
	June YTD 14	June YTD 13	% Change	June YTD 14	June YTD 13	% Change	June YTD 14	June YTD 13	% Change
TOTAL SALES ⁽¹⁾	\$21,198	\$21,681	-2	\$8,574	\$8,823	-3	\$12,624	\$12,858	-2
PHARMACEUTICAL	17,538	18,201	-4	6,592	6,945	-5	10,946	11,257	-3
Primary Care and Women's Health									
Cardiovascular									
Zetia	1,328	1,279	4	732	685	7	596	594	
Vytorin	777	810	-4	277	326	-15	500	484	3
Diabetes & Obesity									
Januvia	1,916	1,956	-2	1,040	1,033	1	876	923	-5
Janumet	995	883	13	448	432	4	547	451	21
General Medicine & Women's Health									
NuvaRing	346	322	7	215	197	9	131	125	5
Implanon	221	187	18	127	94	35	94	93	1
Follistim AQ	213	257	-17	64	103	-37	148	154	-4
Dulera	205	147	39	194	140	39	10	7	46
Hospital and Specialty									
Hepatitis									
PegIntron	216	268	-19	12	23	-45	203	245	-17
Victrelis	105	226	-53	5	88	-94	100	138	-27
HIV									
Isentress	843	775	9	419	405	3	424	370	15
Hospital									
Cancidas	322	326	-1	11	15	-25	311	311	
Invanz	249	230	8	123	115	7	125	115	9
Noxafil	172	136	26	55	40	37	118	97	22
Bridion	155	131	18				155	131	18
Primaxin	151	168	-10	3	7	-57	148	161	-8
Immunology									
Remicade	1,211	1,076	13				1,211	1,076	13
Simponi	330	228	45				330	228	45
Other									
Cosopt / Trusopt	198	209	-5	1	9	-87	197	200	-1
Oncology									
Emend	266	250	6	148	140	6	118	110	7
Temodar	176	434	-59	4	215	-98	172	219	-21
Diversified Brands									
Respiratory									
Nasonex	570	711	-20	274	327	-16	295	383	-23
Singulair	554	618	-10	13	16	-19	541	601	-10
Clarinx	131	125	5	11	7	56	120	118	1
Other									
Cozaar / Hyzaar	419	522	-20	14	16	-9	405	506	-20
Arcoxia	268	242	11				268	242	11
Fosamax	245	281	-13	9	9		235	271	-13
Zocor	133	156	-15	10	12	-17	123	144	-15
Propecia	131	135	-3	10	12	-17	122	124	-2
Remeron	90	106	-15	2	2	-26	88	103	-15
Vaccines									
Gardasil	792	773	3	564	499	13	228	273	-17
ProQuad, M-M-R II and Varivax	606	611	-1	517	547	-6	89	64	38
RotaTeq	316	306	3	231	228	2	85	78	9
Zostavax	298	309	-3	245	274	-11	53	35	52
Pneumovax 23	203	219	-7	168	166	1	35	53	-34
Other Pharmaceutical ⁽²⁾	2,387	2,789	-14	646	763	-15	1,745	2,027	-14
ANIMAL HEALTH	1,685	1,691		362	450	-20	1,323	1,241	7
CONSUMER CARE ⁽³⁾	1,130	1,061	6	796	790	1	334	271	23
Claritin OTC	323	256	26	249	254	-2	74	2	*
Other Revenues ⁽⁴⁾	845	727	16	825	638	29	20	89	-77
Astra	463	507	-9	463	507	-9			

* 100% or greater

⁽¹⁾ Only select products are shown.

⁽²⁾ Includes Pharmaceutical products not individually shown above. Other Vaccines sales included in Other Pharmaceutical were \$175 million and \$140 million on a global basis for June YTD 2014 and 2013, respectively.

⁽³⁾ June YTD 2013 includes a reduction to Consumer Care sales that reflects the termination in China of distribution arrangements and a reversal of sales previously made to those distributors, together with associated termination costs.

⁽⁴⁾ Other revenues are comprised primarily of alliance revenue, third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities. On October 1, 2013, the Company divested a substantial portion of its third-party manufacturing sales. Other revenues in June YTD 2014 include \$232 million of revenue recognized in connection with the sale of U.S. *Saphris* rights.

MERCK & CO., INC.
PHARMACEUTICAL GEOGRAPHIC SALES
(AMOUNTS IN MILLIONS)
(UNAUDITED)

Table 3c

	2014			2013						% Change	
	1Q	2Q	June YTD	1Q	2Q	June YTD	3Q	4Q	Full Year	2Q	June YTD
TOTAL PHARMACEUTICAL	\$8,451	\$9,087	\$17,538	\$8,891	\$9,310	\$18,201	\$9,475	\$9,760	\$37,437	-2	-4
United States	3,130	3,462	6,592	3,256	3,689	6,945	4,148	3,761	14,854	-6	-5
% Pharmaceutical Sales	37.0%	38.1%	37.6%	36.6%	39.6%	38.2%	43.8%	38.5%	39.7%		
Europe ⁽¹⁾	2,478	2,537	5,015	2,465	2,343	4,808	2,276	2,535	9,619	8	4
% Pharmaceutical Sales	29.3%	27.9%	28.6%	27.7%	25.2%	26.4%	24.0%	26.0%	25.7%		
Japan	835	859	1,694	1,034	948	1,982	893	1,074	3,949	-9	-15
% Pharmaceutical Sales	9.9%	9.5%	9.7%	11.6%	10.2%	10.9%	9.4%	11.0%	10.5%		
Asia Pacific	809	840	1,650	822	874	1,696	799	870	3,365	-4	-3
% Pharmaceutical Sales	9.6%	9.2%	9.4%	9.2%	9.4%	9.3%	8.4%	8.9%	9.0%		
China	282	309	592	271	297	568	242	293	1,103	4	4
Latin America	538	668	1,205	596	676	1,272	628	667	2,567	-2	-5
% Pharmaceutical Sales	6.4%	7.3%	6.9%	6.7%	7.3%	7.0%	6.6%	6.8%	6.9%		
Eastern Europe/Middle East Africa	415	459	874	439	479	917	431	534	1,883	-4	-5
% Pharmaceutical Sales	4.9%	5.1%	5.0%	4.9%	5.1%	5.0%	4.5%	5.5%	5.0%		
Canada	200	218	418	245	257	502	253	276	1,030	-15	-17
% Pharmaceutical Sales	2.4%	2.4%	2.4%	2.8%	2.8%	2.8%	2.7%	2.8%	2.8%		
Other	46	44	90	34	45	79	47	43	170	-3	13
% Pharmaceutical Sales	0.5%	0.5%	0.5%	0.4%	0.5%	0.4%	0.5%	0.4%	0.5%		

(1) Europe primarily represents all European Union countries and the European Union accession markets.

MERCK & CO., INC.
SECOND QUARTER 2014
EQUITY INCOME / JV SALES / OTHER (INCOME) EXPENSE, NET - GAAP
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 4

EQUITY INCOME FROM AFFILIATES

	2Q14	2Q13	June YTD 2014	June YTD 2013
ASTRAZENECA LP ⁽¹⁾	\$ 94	\$ 105	\$ 192	\$ 230
Other ⁽²⁾	(2)	11	25	19
TOTAL	\$ 92	\$ 116	\$ 217	\$ 249

⁽¹⁾ Effective July 1, 2014, the Company no longer records equity income from AstraZeneca LP.

⁽²⁾ Includes results for Sanofi Pasteur MSD.

SANOFI PASTEUR MSD JOINT VENTURE SALES DETAIL

All sales reported here are end-market JV sales, presented on a "NET" basis.

	2Q14	2Q13	June YTD 2014	June YTD 2013
GARDASIL	\$ 55	\$ 61	\$ 119	\$ 134
OTHER VIRAL VACCINES	21	27	46	56
ROTATEQ	15	13	32	27
HEPATITIS VACCINES	8	7	17	15
ZOSTAVAX	30	-	37	-
Other Vaccines	84	99	179	205
TOTAL SANOFI PASTEUR MSD SALES	\$ 213	\$ 207	\$ 430	\$ 437

OTHER (INCOME) EXPENSE, NET

	2Q14	2Q13	June YTD 2014	June YTD 2013
INTEREST INCOME	\$ (59)	\$ (65)	\$ (121)	\$ (122)
INTEREST EXPENSE	188	201	376	385
EXCHANGE LOSSES	20	55	53	267
Other, net ⁽¹⁾	(707)	10	(904)	(46)
TOTAL	\$ (558)	\$ 201	\$ (596)	\$ 484

⁽¹⁾ Other, net in the second quarter and first six months of 2014 includes a \$741 million gain on AstraZeneca's option exercise.